LASE Innovation — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LASE Innovation is an early-stage, private company based in Cambridge, MA, founded in 2019. It has developed a patented laser particle (LP™) technology for optical cell barcoding, allowing researchers to track hundreds of thousands to millions of individual cells over time and across different experimental modalities. The company operates primarily as a platform tools provider, with its first commercial service launched in collaboration with Talon Biomarkers in 2025. It has secured non-dilutive funding through SBIR grants from the National Cancer Institute (NCI) and is focused on enabling next-generation single-cell analysis for drug discovery and biomarker development.

OncologyImmunology

Technology Platform

LP™ (Laser Particle) Optical Cell Barcoding platform using light-emitting particles with narrowband emission for massively multiplexed tracking of individual cells across flow cytometry, sequencing, and microscopy.

Opportunities

The growing demand for high-dimensional, longitudinal single-cell data in immunology and oncology research presents a major opportunity.

LASE's technology enables unique multi-modal cell tracking, which is critical for understanding dynamic biological processes in drug development and biomarker discovery.

Partnerships with CROs and larger tool companies could accelerate market penetration.

Risk Factors

Key risks include competition from established single-cell analysis companies, the challenge of convincing researchers to adopt a new and potentially complex workflow, and the execution risk of scaling the technology from a grant-funded project to a robust, commercially successful platform.

Future growth is dependent on securing additional funding beyond SBIR grants.

Competitive Landscape

LASE competes in the single-cell analysis market against major players like 10x Genomics (sequencing), BD and Standard BioTools (flow/mass cytometry), and startups in cell barcoding. Its differentiation lies in enabling longitudinal tracking of the same cell across platforms, a capability not fully addressed by current snapshot-based technologies.

More companies in Digital Health & Biotech SaaS →More companies in United States →